首页> 美国卫生研究院文献>Clinical and Experimental Immunology >Tryptic peptides of human thyroglobulin: II. Immunoreactivity with sera from patients with thyroid diseases.
【2h】

Tryptic peptides of human thyroglobulin: II. Immunoreactivity with sera from patients with thyroid diseases.

机译:人甲状腺球蛋白的胰蛋白酶肽:II。甲状腺疾病患者血清的免疫反应性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tryptic peptides of human thyroglobulin (Tg) were analysed by Western immunoblot for their reactivity to circulating autoantibodies from patients with Hashimoto's thyroiditis (HT), Graves' disease (GD) and thyroid carcinoma, and from normal human controls. Low molecular weight peptides were released after 4 h incubation of Tg with trypsin. The sera of thyroid disease patients reacted with several peptides, but predominantly bound three peptides with apparent molecular weights (MWap) of 25 kD, 20 kD, and 15 kD; the sera of normal individuals did not bind these fragments of Tg. The pattern of tryptic peptides recognized by the majority of sera from GD patients differed from that recognized by sera from most patients with HT. Autoantibodies from both groups of patients recognized a 15-kD peptide with a high frequency, but the sera from 26/43 (60%) GD patients also recognized a peptide with MWap of 25 kD, whereas the sera from 22/35 (63%) of HT patients recognized a 20-kD peptide. A few sera from patients with thyroid carcinoma reacted with peptides with MWap of 15 and 20-kD, and none bound the 25-kD peptide. The immunoreactivity of autoantibodies in HT sera to the 20-kD peptide paralleled the competitive inhibition of the MoAb 137C1 by these sera. In addition, MoAb 137C1 and Hashimoto's sera showed the same Western immunoblot-binding pattern to Tg tryptic peptides, suggesting that a Hashimoto-associated epitope and the 137C1-binding site are found on the same peptide. These findings suggest that distinct peptides are recognized by Tg autoantibodies from patients with different thyroid diseases.
机译:通过Western免疫印迹分析了人类甲状腺球蛋白(Tg)的胰蛋白酶解肽与来自桥本甲状腺炎(HT),格雷夫斯病(GD)和甲状腺癌以及正常人类对照的循环自身抗体的反应性。 Tg与胰蛋白酶孵育4小时后,释放低分子量肽。甲状腺疾病患者的血清与几种肽反应,但主要结合三种表观分子量(MWap)分别为25 kD,20 kD和15 kD的肽。正常人的血清没有结合这些Tg片段。 GD患者的大多数血清所识别的胰蛋白酶肽的模式不同于大多数HT患者的血清所识别的胰蛋白酶肽的模式。两组患者的自身抗体均能高频率识别15 kD肽,但26/43(60%)GD患者的血清也能识别MWap为25 kD的肽,而22/35(63%)的血清)HT患者识别出20 kD肽。甲状腺癌患者的一些血清与MWap为15和20-kD的肽发生反应,而没有结合25-kD的肽。 HT血清中自身抗体对20 kD肽的免疫反应性与这些血清对MoAb 137C1的竞争性抑制作用平行。此外,MoAb 137C1和桥本的血清显示出与Tg胰蛋白酶肽相同的Western免疫印迹结合模式,这表明桥本相关的抗原决定簇和137C1结合位点位于同一肽上。这些发现表明,来自患有不同甲状腺疾病的患者的Tg自身抗体识别出不同的肽。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号